Jordi Monés, MD, PhD, to Introduce First Direct-to-Phase 2 Randomized, Controlled Trial of Optogenetic Therapy in Macular Degeneration Benjamin Bakall, MD, PhD, to Present Durable 3-Year REMAIN Follow-Up Data from the RESTORE Phase 2b/3 Trial of MCO-010 in Retinitis Pigmentosa MONTREAL, July 10, 2026 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision im

IHealthScreen hauled in FDA 510(k) clearance for its AI-powered diagnostic that detects mild diabetic retinopathy in diabetic adults who have gone undiagnosed with the condition. The Richmond Hill, New York-based software and medical device company’s iPredict-DR leverages AI to review color retinal fundus images using its iCare DRSplus camera.The system is non-invasive and is easy to use by any minimally skilled healthcare worker or nurse, the company said in a press release. The platform was de

A machine learning model adjusts toxin readings for water-quality variability, enabling faster, lower-cost on-site testing without repeated recalibration CHUNGCHEONG PROVINCE, South Korea, July 10, 2026 /PRNewswire/ -- Portable screen-printed carbon electrode (SPCE) biosensors offer a rapid and low-cost way to detect microcystin-lysine-arginine (MC-LR), an extremely potent toxin produced by cyanobacteria during harmful algal blooms in freshwater. Even at low concentrations, MC-LR can damage the

Strategic Partnership Gives Brands Direct Access to Top Patented Functional Ingredient Stacks LOS ANGELES, July 10, 2026 /PRNewswire/ -- Axiom Foods and NNB Nutrition announced today a strategic partnership to help brands formulate the next generation of "Protein +" functional plant-based nutrition products across Asia and North America. Together, they aim to service the global demand for functional food ingredients, currently pegged at $437.6B with growth expected to reach $983.2B by 2034 (10.7

Proprietary small-molecule formulation extends beyond conventional ROCK inhibitors to accelerate recovery and improve reproducibility in stem cell and organoid research. MONMOUTH JUNCTION, N.J., July 10, 2026 /PRNewswire/ -- TheWell Bioscience, a leader in xeno-free 3D cell culture technologies, today announced the launch of RocketCell™ Cell Viability Enhancer (1000X), a next-generation cell recovery reagent engineered to maximize cell survival, metabolic recovery, and proliferation following pa

Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential boost in its competition with Johnson & Johnson’s powerhouse Darzalex. Sanofi’s new formulation, which is dubbed Sarclisa Escena, now becomes the first subcutaneous anticancer drug that can be administered manually or by an on-body injector (OBI). The endorsement for Sarclisa Escena applies to each of the indications for which its intravenous (IV) formulation is approved. Th

Vancouver, Canada, July 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage a biotech company developing novel, non-hallucinogenic, next-generation, neuroplastogen-derived therapeutics to solve major under-treated mental health problems, with a focus on Alcohol Use Disorder and other addiction related diagnoses, today announced that it has submitted a formal response to the U.S. Department of Health and Human Services (HHS) Request for Information (RFI) about

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage & Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle & Vision Summit, taking place July 16th in Boston, Massachusetts. T

This is Part 2 of a two-part series examining how Missouri's Children's Mercy and GE HealthCare partnered to help prepare the region's healthcare system for the World Cup. In Part 1 , Children's Mercy in Kansas City and GE HealthCare discussed how years of planning, regional coordination and emergency preparedness helped the hospital system prepare for the influx of visitors during the FIFA World Cup 2026 . Behind those efforts is a critical piece of technology that gives hospitals real-time vis

Hansoh Pharmaceutical’s pair of much-hyped ADCs continue to justify partner GSK’s decision to elevate them to “priority asset” status. The latest evidence of the therapies’ potential comes from a phase 3 study in China of risvutatug rezetecan (ris-rez), a B7-H3-targeted ADC. The trial hit its primary endpoint of overall survival in patients with advanced or relapsed small-cell lung cancer (SCLC) when compared against standard-of-care chemotherapy, according to a July 10 release . The companies t